{"id":"reboxetine","rwe":[],"tags":[{"label":"reboxetine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Sodium-dependent noradrenaline transporter","category":"target"},{"label":"SLC6A2","category":"gene"},{"label":"SLC6A4","category":"gene"},{"label":"SLC6A3","category":"gene"},{"label":"N06AX18","category":"atc"},{"label":"Active","category":"status"},{"label":"Major depressive disorder","category":"indication"},{"label":"Adrenergic Agents","category":"pharmacology"},{"label":"Adrenergic Uptake Inhibitors","category":"pharmacology"},{"label":"Antidepressive Agents","category":"pharmacology"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Membrane Transport Modulators","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"},{"label":"Neurotransmitter Uptake Inhibitors","category":"pharmacology"},{"label":"Psychotropic Drugs","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":49.922,"date":"","count":9,"signal":"Convulsive threshold lowered","source":"DrugCentral FAERS","actionTaken":"Reported 9 times (LLR=50)"},{"llr":49.605,"date":"","count":9,"signal":"Parasomnia","source":"DrugCentral FAERS","actionTaken":"Reported 9 times (LLR=50)"}],"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=REBOXETINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:03:09.550229+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:03:16.640003+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=REBOXETINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:03:17.783348+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Norepinephrine transporter inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:03:18.353943+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL14370/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:03:18.244004+00:00"}},"allNames":"edronax","offLabel":[],"synonyms":["reboxetine mesilate","reboxetine mesylate","edronax","reboxetine","norebox","reboxitine"],"timeline":[{"date":"1997-01-01","type":"positive","source":"DrugCentral","milestone":"YEAR INTRODUCED approval"}],"approvals":[{"date":"1997-01-01","orphan":false,"company":"","regulator":"YEAR INTRODUCED"}],"brandName":"Edronax","ecosystem":[{"indication":"Major depressive disorder","otherDrugs":[{"name":"brexpiprazole","slug":"brexpiprazole","company":"Otsuka Pharm Co Ltd"},{"name":"bupropion","slug":"bupropion","company":"Glaxosmithkline"},{"name":"citalopram","slug":"citalopram","company":"Forest Labs"},{"name":"desvenlafaxine","slug":"desvenlafaxine","company":"Wyeth Pharms Inc"}],"globalPrevalence":280000000}],"mechanism":{"target":"Sodium-dependent noradrenaline transporter","targets":[{"gene":"SLC6A2","source":"DrugCentral","target":"Sodium-dependent noradrenaline transporter","protein":"Sodium-dependent noradrenaline transporter"},{"gene":"SLC6A4","source":"DrugCentral","target":"Sodium-dependent serotonin transporter","protein":"Sodium-dependent serotonin transporter"},{"gene":"SLC6A3","source":"DrugCentral","target":"Sodium-dependent dopamine transporter","protein":"Sodium-dependent dopamine transporter"},{"gene":"HTR2C","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2C","protein":"5-hydroxytryptamine receptor 2C"},{"gene":"HTR6","source":"DrugCentral","target":"5-hydroxytryptamine receptor 6","protein":"5-hydroxytryptamine receptor 6"},{"gene":"KCNJ3","source":"DrugCentral","target":"Kir3.1/Kir3.4","protein":"G protein-activated inward rectifier potassium channel 1"},{"gene":"KCNJ5","source":"DrugCentral","target":"Kir3.1/Kir3.4","protein":"G protein-activated inward rectifier potassium channel 4"},{"gene":"KCNJ6","source":"DrugCentral","target":"Kir3.1/Kir3.2","protein":"G protein-activated inward rectifier potassium channel 2"}],"modality":"Small Molecule","drugClass":"reboxetine","explanation":"","oneSentence":"","technicalDetail":"Edronax selectively inhibits the sodium-dependent noradrenaline transporter (NET), preventing the reuptake of noradrenaline and increasing its availability in the synaptic cleft, thereby enhancing noradrenergic neurotransmission."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2361","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=REBOXETINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=REBOXETINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:33:18.265268","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:03:20.406667+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"tryptophan","drugSlug":"tryptophan","fdaApproval":"","relationship":"same-class"},{"drugName":"nomifensine","drugSlug":"nomifensine","fdaApproval":"","relationship":"same-class"},{"drugName":"trazodone","drugSlug":"trazodone","fdaApproval":"1981-12-24","patentExpiry":"Mar 27, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"nefazodone","drugSlug":"nefazodone","fdaApproval":"1994-12-22","genericCount":9,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"viloxazine","drugSlug":"viloxazine","fdaApproval":"2021-04-02","patentExpiry":"Sep 4, 2029","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"mirtazapine","drugSlug":"mirtazapine","fdaApproval":"1996-06-14","genericCount":19,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"bupropion","drugSlug":"bupropion","fdaApproval":"1985-12-30","patentExpiry":"Jun 27, 2026","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"venlafaxine","drugSlug":"venlafaxine","fdaApproval":"1993-12-28","genericCount":41,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"milnacipran","drugSlug":"milnacipran","fdaApproval":"2009-01-14","patentExpiry":"Sep 19, 2029","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"duloxetine","drugSlug":"duloxetine","fdaApproval":"2004-08-03","patentExpiry":"Apr 13, 2037","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"desvenlafaxine","drugSlug":"desvenlafaxine","fdaApproval":"2008-02-29","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"vilazodone","drugSlug":"vilazodone","fdaApproval":"2011-01-21","genericCount":5,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"vortioxetine","drugSlug":"vortioxetine","fdaApproval":"2013-09-30","patentExpiry":"Sep 21, 2032","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"esketamine","drugSlug":"esketamine","fdaApproval":"2019-05-03","patentExpiry":"Sep 10, 2035","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"levomilnacipran","drugSlug":"levomilnacipran","fdaApproval":"2013-07-25","patentExpiry":"May 23, 2032","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"brexanolone","drugSlug":"brexanolone","fdaApproval":"2019-03-19","patentExpiry":"Nov 27, 2033","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"reboxetine","indications":{"approved":[{"name":"Major depressive disorder","source":"DrugCentral","snomedId":370143000,"regulator":"FDA","usPrevalence":21000000,"globalPrevalence":280000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"tryptophan","brandName":"tryptophan","genericName":"tryptophan","approvalYear":"","relationship":"same-class"},{"drugId":"nomifensine","brandName":"nomifensine","genericName":"nomifensine","approvalYear":"","relationship":"same-class"},{"drugId":"trazodone","brandName":"trazodone","genericName":"trazodone","approvalYear":"1981","relationship":"same-class"},{"drugId":"nefazodone","brandName":"nefazodone","genericName":"nefazodone","approvalYear":"1994","relationship":"same-class"},{"drugId":"viloxazine","brandName":"viloxazine","genericName":"viloxazine","approvalYear":"2021","relationship":"same-class"},{"drugId":"mirtazapine","brandName":"mirtazapine","genericName":"mirtazapine","approvalYear":"1996","relationship":"same-class"},{"drugId":"bupropion","brandName":"bupropion","genericName":"bupropion","approvalYear":"1985","relationship":"same-class"},{"drugId":"venlafaxine","brandName":"venlafaxine","genericName":"venlafaxine","approvalYear":"1993","relationship":"same-class"},{"drugId":"milnacipran","brandName":"milnacipran","genericName":"milnacipran","approvalYear":"2009","relationship":"same-class"},{"drugId":"duloxetine","brandName":"duloxetine","genericName":"duloxetine","approvalYear":"2004","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT05113745","phase":"PHASE3","title":"A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy (ENCORE)","status":"COMPLETED","sponsor":"Axsome Therapeutics, Inc.","startDate":"2021-10-20","conditions":["Narcolepsy","Cataplexy","Excessive Daytime Sleepiness"],"enrollment":68,"completionDate":"2024-11-15"},{"nctId":"NCT05880342","phase":"PHASE3","title":"The Role of the Brain in Mental and Physical Fatigue","status":"RECRUITING","sponsor":"Vrije Universiteit Brussel","startDate":"2023-05-03","conditions":["Fatigue"],"enrollment":62,"completionDate":"2025-12-31"},{"nctId":"NCT05133804","phase":"PHASE2","title":"Efficacy of Reboxetine and Methylphenidate Treatment on Attentional, Sensory and Emotional Dysregulation in Adults With PTSD","status":"RECRUITING","sponsor":"University of Haifa","startDate":"2022-06-01","conditions":["Posttraumatic Stress Disorder"],"enrollment":53,"completionDate":"2025-12-01"},{"nctId":"NCT05059223","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy","status":"COMPLETED","sponsor":"Axsome Therapeutics, Inc.","startDate":"2021-09-15","conditions":["Narcolepsy","Cataplexy","Excessive Daytime Sleepiness"],"enrollment":90,"completionDate":"2024-03-15"},{"nctId":"NCT00853866","phase":"PHASE4","title":"Enhancement of Motor Function with Reboxetine and Transcranial Direct Current Stimulation","status":"COMPLETED","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2009-01","conditions":["Cerebral Stroke"],"enrollment":12,"completionDate":"2010-06"},{"nctId":"NCT05978505","phase":"PHASE2","title":"Reboxetine for Sleep Apnoea After ENT Surgery","status":"RECRUITING","sponsor":"Flinders University","startDate":"2023-08-10","conditions":["Sleep Apnea, Obstructive"],"enrollment":20,"completionDate":"2025-07"},{"nctId":"NCT04384562","phase":"NA","title":"Studying the Role of Brain Molecules for Decision Making","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2020-12-17","conditions":["Decision Making","Healthy"],"enrollment":160,"completionDate":"2021-12-13"},{"nctId":"NCT03881852","phase":"PHASE2","title":"Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment (CONCERT)","status":"COMPLETED","sponsor":"Axsome Therapeutics, Inc.","startDate":"2019-01-30","conditions":["Narcolepsy","Cataplexy Narcolepsy","Excessive Sleepiness"],"enrollment":21,"completionDate":"2019-11-27"},{"nctId":"NCT05952713","phase":"","title":"Comparative Responses to 15 Different Antidepressants in Major Depressive Disorder","status":"COMPLETED","sponsor":"Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital","startDate":"2022-10-01","conditions":["Major Depressive Disorder"],"enrollment":73336,"completionDate":"2023-07-01"},{"nctId":"NCT01719458","phase":"","title":"Norepinephrine Transporter Imaging in Addiction Disorders","status":"WITHDRAWN","sponsor":"Yale University","startDate":"2007-07","conditions":["Obesity","Alcohol Dependence"],"enrollment":0,"completionDate":"2023-01-04"},{"nctId":"NCT05737511","phase":"PHASE4","title":"Efficacy of Hydroxyzine for Patients With Panic Disorder","status":"NOT_YET_RECRUITING","sponsor":"Sultan Qaboos University","startDate":"2023-12-30","conditions":["Panic Disorder"],"enrollment":80,"completionDate":"2026-12-30"},{"nctId":"NCT04097288","phase":"PHASE1","title":"Effects of Single Dose Citalopram and Reboxetine on Urethral and Anal Closure Function on Healthy Female Subjects","status":"COMPLETED","sponsor":"University Hospital Bispebjerg and Frederiksberg","startDate":"2019-09-17","conditions":["Stress Urinary Incontinence","Fecal Incontinence"],"enrollment":24,"completionDate":"2020-05-01"},{"nctId":"NCT00636246","phase":"PHASE2","title":"A Comparison of Sertraline-reboxetine Combination Therapy Versus Sertraline or Reboxetine Monotherapy in the Treatment of Major Depression.","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2004-06","conditions":["Depressive Disorder, Major"],"enrollment":510,"completionDate":"2005-08"},{"nctId":"NCT03957174","phase":"NA","title":"Noradrenaline, Acetylcholine and Dynamic Learning in Healthy Humans","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2019-06-01","conditions":["Healthy"],"enrollment":107,"completionDate":"2020-06-01"},{"nctId":"NCT04371146","phase":"NA","title":"The Role of Dopaminergic and Noradrenergic Neurotransmission in Value- and Salience-based Decision-Making","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2019-07-03","conditions":["Healthy"],"enrollment":120,"completionDate":"2020-02-13"},{"nctId":"NCT02056249","phase":"","title":"Evaluation of the Effect of Hypoglycemia With PET and a Norepinephrine Transporter Ligand","status":"COMPLETED","sponsor":"Yale University","startDate":"2011-06","conditions":["Hypoglycemia"],"enrollment":9,"completionDate":"2017-06"},{"nctId":"NCT00754221","phase":"PHASE3","title":"Open Label Extension Study of [S,S]-Reboxetine in Patients With Fibromyalgia","status":"TERMINATED","sponsor":"Pfizer","startDate":"2008-05","conditions":["Fibromyalgia"],"enrollment":390,"completionDate":"2009-05"},{"nctId":"NCT00334685","phase":"PHASE2","title":"[S,S]-Reboxetine Add-On Trial","status":"TERMINATED","sponsor":"Pfizer","startDate":"2006-08-22","conditions":["Pain"],"enrollment":136,"completionDate":"2007-10-11"},{"nctId":"NCT00625833","phase":"PHASE2","title":"A Trial Of [S,S]-Reboxetine In Patients With Chronic Painful Diabetic Peripheral Neuropathy.","status":"TERMINATED","sponsor":"Pfizer","startDate":"2007-12","conditions":["Diabetic Neuropathies"],"enrollment":330,"completionDate":"2008-11"},{"nctId":"NCT00607256","phase":"PHASE3","title":"Long-term OL Study of [S,S]-RBX in Patients With Fibromyalgia","status":"TERMINATED","sponsor":"Pfizer","startDate":"2007-10-20","conditions":["Fibromyalgia"],"enrollment":500,"completionDate":"2009-05-18"},{"nctId":"NCT00612170","phase":"PHASE3","title":"A 14-week, Multi-center Study of [S,S]-Reboxetine in Patients With Fibromyalgia.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-12","conditions":["Fibromyalgia"],"enrollment":1129,"completionDate":"2009-05"},{"nctId":"NCT00562055","phase":"PHASE2","title":"Double-Blind, Four Week Trial Of [S,S]-Reboxetine And Atomoxetine In Adults With Attention Deficit Hyperactivity Disorder.","status":"WITHDRAWN","sponsor":"Pfizer","startDate":"2007-11","conditions":["Attention Deficit Hyperactivity Disorder"],"enrollment":0,"completionDate":""},{"nctId":"NCT02374567","phase":"PHASE3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2015-01","conditions":["Dementia","Depression","Schizophrenia","Psychosomatic Disorders","Anxiety Disorders"],"enrollment":407,"completionDate":"2017-06-28"},{"nctId":"NCT02179268","phase":"PHASE3","title":"Antidepressants and Bone Mineral Density","status":"COMPLETED","sponsor":"Guiyang Medical University","startDate":"2012-03","conditions":["Bone Mineral Density Quantitative Trait Locus 7"],"enrollment":203,"completionDate":"2014-04"},{"nctId":"NCT00357825","phase":"PHASE2","title":"A Trial Assessing The Effectiveness and Safety of [S,S]-Reboxetine in Patients With Fibromyalgia","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-08","conditions":["Pain"],"enrollment":246,"completionDate":"2007-03"},{"nctId":"NCT00421369","phase":"NA","title":"Augmentation of the Antidepressant Action of Sertraline With Triiodothyronine (T3)and Reboxetine: Clinical Efficacy, Adverse Effects and Predictors of Response.","status":"COMPLETED","sponsor":"Hadassah Medical Organization","startDate":"2007-09","conditions":["Major Depressive Disorder"],"enrollment":35,"completionDate":"2011-08"},{"nctId":"NCT00886886","phase":"PHASE1","title":"Interaction Between Reboxetine and 3,4-Methylenedioxymethamphetamine: Pharmacodynamics (PD) and Pharmacokinetics (PK)","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2009-04","conditions":["Mood Disorder","Substance-related Disorders","Amphetamine-related Disorders"],"enrollment":16,"completionDate":"2010-03"},{"nctId":"NCT00288652","phase":"PHASE2","title":"[S,S]-Reboxetine Dose-Range Finding Trial","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-03","conditions":["Pain"],"enrollment":280,"completionDate":"2007-02"},{"nctId":"NCT00444548","phase":"NA","title":"Evaluation of A Novel Methodology in the Assessment of Urethral Function Using [S,S]-Reboxetine in Healthy Volunteers","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-05","conditions":["Healthy"],"enrollment":12,"completionDate":"2007-07"},{"nctId":"NCT00141128","phase":"PHASE2","title":"Evaluation Of A Novel Methodology In The Assessment Of Urethral Function Using SS-RBX.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2005-12","conditions":["Urinary Incontinence, Stress"],"enrollment":18,"completionDate":"2006-06"},{"nctId":"NCT00348894","phase":"PHASE2","title":"[S,S]-Reboxetine Long Term Safety Study In Chronic Painful Diabetic Peripheral Neuropathy.","status":"TERMINATED","sponsor":"Pfizer","startDate":"2006-07","conditions":["Pain"],"enrollment":136,"completionDate":"2007-10"},{"nctId":"NCT00353808","phase":"PHASE2","title":"A Trial Assessing The Long Term Safety And Tolerability Of [S,S]-Reboxetine In Patients With Post-Shingles Pain.","status":"TERMINATED","sponsor":"Pfizer","startDate":"2006-07","conditions":["Pain"],"enrollment":112,"completionDate":"2007-10"},{"nctId":"NCT00138749","phase":"PHASE2","title":"An 8 Week Study Looking At The Efficacy, Toleration And Safety Of SS-RBX For Stress Urinary Incontinence.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2004-11","conditions":["Urinary Incontinence, Stress"],"enrollment":402,"completionDate":"2006-08"},{"nctId":"NCT01300364","phase":"PHASE4","title":"Reboxetine and Citalopram as an Adjunct Treatment to Second Generation Antipsychotics in the Treatment of Negative Symptoms of Schizophrenia","status":"UNKNOWN","sponsor":"Fundació Sant Joan de Déu","startDate":"2008-11","conditions":["Schizophrenia"],"enrollment":249,"completionDate":""},{"nctId":"NCT00209807","phase":"PHASE4","title":"Effect of Escitalopram vs. Reboxetine on Gastro-intestinal Sensitivity of Patients With Major Depressive Disorder","status":"UNKNOWN","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","startDate":"2005-09","conditions":["Major Depression","Pain","Abdominal Pain"],"enrollment":42,"completionDate":"2011-04"},{"nctId":"NCT00993876","phase":"NA","title":"Cognitive Flexibility in Major Depression in the Course of Pharmacological and Psychotherapeutic Treatment","status":"COMPLETED","sponsor":"Zentrum für Integrative Psychiatrie","startDate":"2005-08","conditions":["Cognitive Performance in Major Depression"],"enrollment":45,"completionDate":"2008-08"},{"nctId":"NCT00354094","phase":"PHASE2","title":"[S,S]-Reboxetine Long Term Safety Study In Post-Shingles Pain.","status":"TERMINATED","sponsor":"Pfizer","startDate":"2006-11","conditions":["Pain"],"enrollment":600,"completionDate":"2007-10"},{"nctId":"NCT00426946","phase":"PHASE4","title":"Reboxetine Treatment in Depressed Children and Adolescents an 8-Week, Open Study","status":"UNKNOWN","sponsor":"Geha Mental Health Center","startDate":"2005-01","conditions":["Depression"],"enrollment":60,"completionDate":""},{"nctId":"NCT00409201","phase":"PHASE1","title":"Reboxetine Adjuvant Therapy for the Treatment of Schizophrenia","status":"UNKNOWN","sponsor":"Abarbanel Mental Health Center","startDate":"2006-03","conditions":["Schizophrenia"],"enrollment":30,"completionDate":"2006-11"},{"nctId":"NCT00143442","phase":"PHASE2","title":"Study of [S,S]-Reboxetine in Patients With Postherpetic Neuralgia, Who Are Gabapentin Treatment Failures","status":"COMPLETED","sponsor":"Pfizer","startDate":"2003-12","conditions":["Pain"],"enrollment":184,"completionDate":"2004-10"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NUI":"N0000171792","NDDF":"006792","UNII":"947S0YZ36I","VUID":"4025264","CHEBI":"CHEBI:135342","VANDF":"4025263","INN_ID":"5858","RXNORM":"153494","UMLSCUI":"C0168388","chemblId":"CHEMBL14370","ChEMBL_ID":"CHEMBL180101","KEGG_DRUG":"D02573","DRUGBANK_ID":"DB00234","PDB_CHEM_ID":" 41X","PUBCHEM_CID":"127151","SNOMEDCT_US":"321995004","IUPHAR_LIGAND_ID":"4808","SECONDARY_CAS_RN":"98769-84-7","MESH_DESCRIPTOR_UI":"D000077593"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"10.0 hours","clearance":"0.82 mL/min/kg","bioavailability":"94%","fractionUnbound":"0.019%","volumeOfDistribution":"0.65 L/kg"},"publicationCount":955,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"N06AX18","allCodes":["N06AX18"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"1997","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"OTHER","regulator":"YEAR INTRODUCED","status":"approved","approval_date":"1997-01-01T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:03:20.406667+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}